Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
08/2002
08/28/2002EP1181272B1 Process for the preparation of pure citalopram
08/28/2002EP1140898B1 Amide and urea derivatives as 5-ht reuptake inhibitors and as 5-ht1b/1d ligands
08/28/2002EP0973731B1 Hydroxamic acid derivatives
08/28/2002EP0918777B1 SELECTED DERIVATIVES OF K-252a
08/28/2002EP0892804B1 Isoxazolidine derivatives
08/28/2002EP0856001B1 Pyrimidine derivatives as 5ht2c receptor antagonists
08/28/2002EP0822828B1 Isolated 55 to 75 kda protein which binds to prion protein
08/28/2002EP0819002B1 USE OF IMIDAZO-[1,2-a]PYRIDINE-3-ACETAMIDE DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF NEUROPSYCHIATRIC SYNDROMES ASSOCIATED WITH DISFUNCTION OF THE NEURAL CIRCUITS OF THE BASAL GANGLIA
08/28/2002CN1366526A Process for preparation of pure citalopram
08/28/2002CN1366525A Method for preparation of pure citalopram
08/28/2002CN1366521A Substituted 1-aza-2-imino heterocycles and their use as nicotinic acetylcholine receptors activators
08/28/2002CN1366520A Medicine
08/28/2002CN1366519A Phenoxazine compounds, its pharmaceutical compositions and medical use
08/28/2002CN1365973A New cycloheplene compound, its preparation method and medicine composition containing same
08/28/2002CN1365812A Nano medicine 'Hongling' and its preparing process
08/28/2002CN1365808A Nano medicine 'Guilu Bushen' and its preparing process
08/28/2002CN1365807A Nano medicine 'Kanlisha' and its preparing process
08/28/2002CN1365794A Nano medicine 'Xingnaojing' and its preparing process
08/28/2002CN1365785A Nano medicine 'Anshen Buxin' and its preparing process
08/28/2002CN1365775A Nano medicine 'Niuhuang Zhenjing' and its preparing process
08/28/2002CN1365765A Nano medicine 'Zhuangyuan' and its preparing process
08/28/2002CN1365760A Nano medicine 'Zhuli Datan' and its preparing process
08/28/2002CN1365755A Nano medicine 'Yuzhen' and its preparing process
08/28/2002CN1365754A Nano medicine 'Yixian' and its preparing process
08/28/2002CN1365749A Nano medicine 'Xiongju Shangqing' and its preparing process
08/28/2002CN1365720A Nano 25-component pearl medicine and its preparing process
08/28/2002CN1365700A Nano 25-component coral medicine and its preparing process
08/28/2002CN1365697A Nano medicine 'Naoling' and its preparing process
08/28/2002CN1089765C 1H-pyrido [3,4-b] indole-4-carboxamide derivatives, preparation and application thereof in therapeutics
08/28/2002CN1089764C Substituted heterocyclic compounds, preparation method thereof and pharmaceutical compositions containing same
08/28/2002CN1089762C Benzimidazole compounds and their use as modulators of GABAA receptor complex
08/28/2002CN1089759C Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
08/28/2002CN1089585C Use of levobupivacaine in facial surgery
08/27/2002US6441165 Process for the preparation of 11-amino-3-chloro-6, 11-dihydro-5, 5-dioxo-6-methyl-dibenzo[c,f][1,2]thiazepine and application to the synthesis of tianeptine
08/27/2002US6441153 Human carboxypeptidases and polynucleotides encoding the same
08/27/2002US6441149 Isolated nucleic acids
08/27/2002US6441049 Administering compound effective to inhibit binding of an amyloid beta peptide with alpha-7 nicotinic acetylcholine receptors
08/27/2002US6441048 Methods of treating affective disorders using derivatives of (-)-venlafaxine
08/27/2002US6441015 Tetrazole compounds as thyroid receptor ligands
08/27/2002US6441014 Antiinflammatory agent, useful for treating cylcoocygenase-2 associated disorders
08/27/2002US6441013 5-ht6 receptor antagonists for treating central nervous system disorders
08/27/2002US6441012 Chemical compounds
08/27/2002US6441011 Combined preparation consisting of 2-methylthiazolidine-2,4-dicarboxylic acid and paracetamol
08/27/2002US6441007 Treating central nervous system disorders with pyridyloxylalkylamines and phenoxyalkylamines
08/27/2002US6441006 Pharmaceutical compositions and methods for use
08/27/2002US6441000 Compounds useful in therapy
08/27/2002US6440996 Monomeric and dimeric heterocycles, and therapeutic uses thereof
08/27/2002US6440995 Quinolin-4-yl derivatives
08/27/2002US6440991 Ethers of 7-desmethlrapamycin
08/27/2002US6440979 Aryl isoguanines
08/27/2002US6440976 Iminopyrimidine NMDA NR2B receptor antagonists
08/27/2002US6440973 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
08/27/2002US6440970 Pharmaceutical compositions and methods for use
08/27/2002US6440969 Certain isoquinolinamine and phthalazinamine derivatives: corticotropin-releasing factor receptor CRF1 specific ligands
08/27/2002US6440968 Use of maduraohtalazine derivatives as inhibitors of proinflammatory cytokines
08/27/2002US6440966 Benzenesulfonamide derivatives and their use as MEK inhibitors
08/27/2002US6440965 Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
08/27/2002US6440960 An oxygen or sulfure or sulfure oxide or dioxide containing tricyclic compouund useful for treating the disorder manifesting hypersecretion of corticotropin releasing factor
08/27/2002US6440955 Anti-inflammatory agents
08/27/2002US6440953 Use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion.
08/27/2002US6440742 Recombinant AAV vector-based transduction system and use of same
08/27/2002US6440702 For treatment of motor neuron diseases and muscle degenerative diseases; screening for therapeutic proteins by determining altered electrophoretic binding properties
08/27/2002US6440457 Administering venlafaxine antidepressant time-release agent; sustained release
08/27/2002US6440455 Methods for modulating the axonal outgrowth of central nervous system neurons
08/27/2002US6440387 For decreasing blood cholesterol levels, thereby decreasing risk for developing alzheimer's disease; for post menopausal women
08/27/2002CA2167039C Alkylated (hetero)cyclic compounds; process for preparing the same and pharmaceutical compositions containing them
08/27/2002CA2125888C Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty
08/27/2002CA2062837C 8-substituted purines as selective adenosine receptor agents
08/27/2002CA2045955C Indole derivatives
08/22/2002WO2002065136A2 Yeast screens for agents affecting protein folding
08/22/2002WO2002064796A2 Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use
08/22/2002WO2002064795A2 Putative human enzymes
08/22/2002WO2002064792A2 Molecules for disease detection and treatment
08/22/2002WO2002064787A1 Neurotonin and use thereof
08/22/2002WO2002064785A1 NOVEL CLOCK GENE Bmal2
08/22/2002WO2002064781A2 Regulation of amyloid precursor protein expression by modification of abc transporter expression or activity
08/22/2002WO2002064776A2 Signal transduction proteins 15b3, 15b3-1 and 15b3-2, and related dna sequences
08/22/2002WO2002064772A1 Human nmda receptor splice variant
08/22/2002WO2002064755A2 Post-partum mammalian placenta, its use and placental stem cells therefrom
08/22/2002WO2002064748A2 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
08/22/2002WO2002064742A2 Compounds effecting neuron remodeling and assays for same
08/22/2002WO2002064735A2 Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
08/22/2002WO2002064734A2 Identification of target-specific folding sites in peptides and proteins
08/22/2002WO2002064731A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
08/22/2002WO2002064635A1 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
08/22/2002WO2002064634A2 Human monoclonal antibodies to fc alpha receptor (cd89)
08/22/2002WO2002064627A2 Crystallization of igf-1
08/22/2002WO2002064616A2 Agonists and antagonists of sphingosine-1-phosphate receptors
08/22/2002WO2002064612A2 Human g-protein chemokine receptor (ccr5) hdgnr10
08/22/2002WO2002064603A1 Procedure for the preparation of pure phosphatides and their use in the cosmetic, pharmaceutical and alimentary fields
08/22/2002WO2002064599A1 Bicyclic pyrimidine matrix metalloproteinase inhibitors
08/22/2002WO2002064598A1 Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
08/22/2002WO2002064595A1 Triazolo compounds as mmp inhibitors
08/22/2002WO2002064594A2 6-substituted pyrido-pyrimidines
08/22/2002WO2002064592A1 Tricyclic crf receptor antagonists
08/22/2002WO2002064590A2 Carboline derivatives
08/22/2002WO2002064589A1 Laulimalide derivatives
08/22/2002WO2002064586A2 Heterocyclic inhibitors of erk2 and uses thereof
08/22/2002WO2002064584A1 Phthalayinone-piperidino-derivatives as pde4 inhibitors
08/22/2002WO2002064578A1 Benzo thiadiazine matrix metalloproteinase inhibitors